Afya Dirección

Dirección controles de criterios 2/4

El CEO de Afya's es Virgilio Deloy Gibbon, nombrado en Jul 2019, tiene una permanencia de 4.75 años. posee directamente un 0.41% de las acciones de la empresa, con un valor de $6.10M. La antigüedad media del equipo directivo y de la junta directiva es de 4.8 años y 3.2 años, respectivamente.

Información clave

Virgilio Deloy Gibbon

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	4.8yrs
Participación del CEO	0.4%
Permanencia media de la dirección	4.8yrs
Promedio de permanencia en la Junta Directiva	3.3yrs

Actualizaciones recientes de la dirección

Recent updates

What Type Of Returns Would Afya's(NASDAQ:AFYA) Shareholders Have Earned If They Purchased Their SharesYear Ago?

Dec 24

Afya BOD approves share buyback program

Dec 23

Afya reports Q3 results

Dec 03

Is Afya Limited's (NASDAQ:AFYA) 10% ROE Strong Compared To Its Industry?

Dec 03

CEO

Virgilio Deloy Gibbon (47 yo)

4.8yrs

Permanencia

Mr. Virgilio Deloy Capobianco Gibbon is Chief Executive Officer of Afya Limited since July 2019. He has been the Chief Executive Officer of Afya Brazil since August 2016. Prior to joining us, he was Chief...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Virgilio Deloy Gibbon	Chief Executive Officer	4.8yrs	sin datos	0.41% R$ 6.7m
Luis Andre Blanco	Chief Financial Officer	4.1yrs	sin datos	0.019% R$ 313.7k
Renata Couto	Investor Relations Executive Manager	no data	sin datos	sin datos
Julio Eduardo de Angeli	Vice President of Continuing Education & Innovation	4.8yrs	sin datos	sin datos

4.8yrs

Permanencia media

50yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de AFYA se considera experimentado (4.8 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Shobhna Mohn	Director	2.8yrs	sin datos	sin datos
Kay Krafft	Co-Chairman	2.8yrs	sin datos	sin datos
Maria Azevedo	Director	2.1yrs	sin datos	sin datos
Vanessa Lopes	Independent Director	4.8yrs	sin datos	sin datos
Nicolau Esteves	Co-Chairman	4.8yrs	sin datos	18.72% R$ 307.7m
Renato Esteves	Director	4.8yrs	sin datos	2.83% R$ 46.5m
Miguel Filisbino De Paula	Independent Director	3.8yrs	sin datos	sin datos
Joao Paulo De Faria	Independent Director	3.8yrs	sin datos	sin datos
Christina Krebs	Director	2yrs	sin datos	sin datos
Benedikt Dalkmann	Director	2yrs	sin datos	sin datos
Marcelo Suhara	Independent Director	no data	sin datos	sin datos

3.3yrs

Permanencia media

48yo

Promedio de edad

Junta con experiencia: AFYA's board of directors are considered experienced (3.3 years average tenure).

Afya Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Afya Limited, Annual General Meeting, Jun 15, 2023

Afya Announces Changes to Its Board of Directors

Less than half of directors are independent

Less than half of directors are independent

Afya Limited Announces Changes to its Board of Directors

Afya Limited, Annual General Meeting, Apr 29, 2022

Recent updates

Afya Limited Reports Unaudited Consolidated Write-Off Results for the First Quarter Ended March 31, 2024

Afya Limited Reports Unaudited Consolidated Write-Off Results for the First Quarter Ended March 31, 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

AFYA: Mr Market Is Mistaken

Is Now The Time To Look At Buying Afya Limited (NASDAQ:AFYA)?

Afya (NASDAQ:AFYA) Seems To Use Debt Quite Sensibly

Afya Is Performing Well And Is A Buy

Full year 2023 earnings: EPS misses analyst expectations

Are Investors Undervaluing Afya Limited (NASDAQ:AFYA) By 39%?

Afya Limited Provides Earnings Guidance for the FY2024

Be Wary Of Afya (NASDAQ:AFYA) And Its Returns On Capital

Afya Limited (NASDAQ:AFYA) Not Lagging Market On Growth Or Pricing

Should You Think About Buying Afya Limited (NASDAQ:AFYA) Now?

Afya Limited to Report Q4, 2023 Results on Mar 14, 2024

These 4 Measures Indicate That Afya (NASDAQ:AFYA) Is Using Debt Reasonably Well

Consensus EPS estimates fall by 14%

Third quarter 2023 earnings: Revenues and EPS in line with analyst expectations

Consensus EPS estimates increase by 11%

Afya (NASDAQ:AFYA) May Have Issues Allocating Its Capital

Afya Limited to Report Q3, 2023 Results on Nov 13, 2023

What Does Afya Limited's (NASDAQ:AFYA) Share Price Indicate?

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Does Afya (NASDAQ:AFYA) Deserve A Spot On Your Watchlist?

Afya Limited to Report Q2, 2023 Results on Aug 28, 2023

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Afya Limited to Report Q1, 2023 Results on May 24, 2023

Afya Limited, Annual General Meeting, Jun 15, 2023

Investor sentiment improves as stock rises 19%

Full year 2022 earnings: EPS misses analyst expectations

Consensus EPS estimates increase by 12%

Afya Announces Changes to Its Board of Directors

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Less than half of directors are independent

Investor sentiment improved over the past week

Afya Limited to Report Q3, 2022 Results on Nov 21, 2022

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Afya GAAP EPS of R$1.12, revenue of R$598.16M; reaffirms FY22 guidance

Investor sentiment improved over the past week

White Brook Capital - AFYA Ltd: Cheap Stock, Good Business, Inherent Growth

Afya Limited to Report Q2, 2022 Results on Aug 22, 2022

Consensus forecasts updated

First quarter 2022 earnings: EPS exceeds analyst expectations

Investor sentiment deteriorated over the past week

Erste Wv GÜTersloh Gmbh signed a basic agreement to acquire additional 2.4% stake in Afya Limited (NasdaqGS:AFYA) from Nicolau Carvalho Esteves Rosângela de Oliveira Tavares Esteves and NRE Capital Ventures Ltd.

Less than half of directors are independent

Afya Limited Announces Changes to its Board of Directors

Afya Limited to Report Q1, 2022 Results on May 23, 2022

Afya Limited, Annual General Meeting, Apr 29, 2022

Afya: Margin And Organic Growth Struggles Remain Top Of Mind

Full year 2021 earnings: EPS misses analyst expectations

Investor sentiment improved over the past week

Consensus forecasts updated

Afya Limited to Report Q4, 2021 Results on Mar 31, 2022

Investor sentiment improved over the past week

Afya On A Grey Price Area

Consensus forecasts updated

Third quarter 2021 earnings: Revenues exceed analyst expectations

Afya: The Longer-Term Growth Story Remains Intact

Afya Limited Provides Earnings Guidance for the Second Half of 2021

Second quarter 2021 earnings released

Director Laura Carvalho has left the company

Bertelsmann SE& Co. KGaA completed the acquisition of 24.7% stake in Afya Limited (NasdaqGS:AFYA) from Bozano Educacional II Fundo de Investimento em Participações manged by Crescera Investimentos.

First quarter 2021 earnings released: EPS R$1.16 (vs R$1.09 in 1Q 2020)

Afya to acquire UNIGRANRIO for R$700M

Afya Limited announced that it has received BRL 822 million in funding from SoftBank Investment Advisers (UK) Limited

Full year 2020 earnings released: EPS R$3.15 (vs R$2.03 in FY 2019)

Afya Limited announced that it expects to receive BRL 822 million in funding from SoftBank Investment Advisers (UK) Limited

Full year 2020 earnings released: EPS R$3.15 (vs R$2.03 in FY 2019)

Afya Limited Provides Revenge Guidance for the Second Half of 2021